EGM
ARQT icon

Engineers Gate Manager’s Arcutis Biotherapeutics ARQT Stock Holding History

Engineers Gate Manager’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-65,977
Closed -$1.55M – 2226
2026
Q1 		$1.55M Sell
65,977
-20,628
-24% -$526K 0.02% 837
2025
Q4 		$2.52M Buy
86,605
+40,322
+87% +$1.03M 0.03% 602
2025
Q3 		$872K Sell
46,283
-51,322
-53% -$809K 0.01% 1225
2025
Q2 		$1.37M Buy
97,605
+31,482
+48% +$441K 0.02% 950
2025
Q1 		$1.03M Buy
+66,123
New +$932K 0.02% 1039
2024
Q4 		– Sell
-34,076
Closed -$317K – 2211
2024
Q3 		$317K Buy
34,076
+7,676
+29% +$75.7K 0.01% 1596
2024
Q2 		$246K Buy
+26,400
New +$239K 0.01% 1563

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Engineers Gate Manager's ARQT Position: Q2 2026 in Review

Engineers Gate Manager sold out of Arcutis Biotherapeutics (ARQT) in Q2 2026, closing a stake of 65,977 shares — an estimated $1.55M sold.

Engineers Gate Manager first reported a position in ARQT in Q2 2024 and held it in 7 quarters. The position peaked at $2.52M in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Engineers Gate Manager reported no remaining Arcutis Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Engineers Gate Manager sold 65,977 Arcutis Biotherapeutics shares in Q2 2026, an estimated $1.55M.
  • Engineers Gate Manager first reported a position in Arcutis Biotherapeutics in Q2 2024 and held it in 7 quarters.
  • Engineers Gate Manager's Arcutis Biotherapeutics position peaked at $2.52M in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.